adenosine has been researched along with Parkinsonian Disorders in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (76.92) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, YR; Aziz, WM; Hamed, MAA; Khalil, WKB; Naser, AFA | 1 |
| Agostinho, P; Andrade, GM; Canas, PM; Carmo, M; Cunha, RA; Duarte, FV; Fernandes, FD; Gonçalves, FQ; Oses, JP; Palmeira, CM; Tomé, AR | 1 |
| Amunts, K; Cremer, JN; Graw, J; Piel, M; Rösch, F; Zilles, K | 1 |
| Chung, EJ; Kim, BJ; Lee, GH; Lee, WY; Yoon, WT | 1 |
| Jalali, A; Kawa, K; Larsen, C; Trevitt, J | 1 |
| Alfinito, PD; Manzino, L; Rijhsinghani, S; Sonsalla, PK; Wang, SP; Zeevalk, GD | 1 |
| Costentin, J; El Yacoubi, M; Vaugeois, JM | 1 |
| Benwell, K; Cliffe, IA; Dourish, CT; Gillespie, RJ; Knight, AR; Lerpiniere, J; Misra, A; Pratt, RM; Revell, D; Upton, R; Weiss, SM | 1 |
| Aguilar, E; Bové, J; Cortés, R; Marin, C; Mengod, G; Serrats, J | 1 |
| Jenner, P; Ramsay Croft, N; Rose, S | 1 |
| Ramkumar, V; Toth, LA; Xie, X | 1 |
| Fukuda, T; Iwata, S; Kaseda, S; Nakagawa, S; Nomoto, M; Shimizu, T | 1 |
| Kase, H | 1 |
2 review(s) available for adenosine and Parkinsonian Disorders
| Article | Year |
|---|---|
Adenosine and dopamine receptor interactions in striatum and caffeine-induced behavioral activation.
Topics: Adenosine; Animals; Behavior, Animal; Caffeine; Corpus Striatum; Dopamine; Humans; Locomotion; Models, Biological; Parkinson Disease; Parkinsonian Disorders; Receptors, Dopamine; Receptors, Purinergic P1; Rodentia; Signal Transduction | 2007 |
New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia.
Topics: Adenosine; Animals; Basal Ganglia; gamma-Aminobutyric Acid; Humans; Models, Neurological; Neurotransmitter Agents; Parkinson Disease; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A2A; Receptors, Purinergic P1; Synaptic Transmission | 2001 |
1 trial(s) available for adenosine and Parkinsonian Disorders
| Article | Year |
|---|---|
MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy.
Topics: 3-Iodobenzylguanidine; Adenosine; Aged; Autonomic Nervous System Diseases; Diagnosis, Differential; Female; Galvanic Skin Response; Heart; Heart Rate; Humans; Iodine Radioisotopes; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; Parkinsonian Disorders; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Respiration; Sensitivity and Specificity; Sympathetic Fibers, Postganglionic; Tomography, Emission-Computed, Single-Photon; Valsalva Maneuver | 2009 |
10 other study(ies) available for adenosine and Parkinsonian Disorders
| Article | Year |
|---|---|
Parkinsonism-like Disease Induced by Rotenone in Rats: Treatment Role of Curcumin, Dopamine Agonist and Adenosine A
Topics: Adenosine; Aged; Animals; Curcumin; Disease Models, Animal; Dopamine Agonists; Humans; Inflammation Mediators; Mice; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Rats; Receptor, Adenosine A2A; Rotenone | 2022 |
Enhanced ATP release and CD73-mediated adenosine formation sustain adenosine A
Topics: 5'-Nucleotidase; Adenosine; Adenosine A2 Receptor Antagonists; Adenosine Diphosphate; Adenosine Triphosphate; Animals; Cell Line, Tumor; Humans; Male; Oxidopamine; Parkinsonian Disorders; Pyrimidines; Rats, Wistar; Receptor, Adenosine A2A; Triazoles | 2019 |
Neurotransmitter receptor density changes in Pitx3ak mice--a model relevant to Parkinson's disease.
Topics: Acetylcholine; Adenosine; Animals; Brain; Dopamine; Epinephrine; gamma-Aminobutyric Acid; Homeodomain Proteins; Homozygote; Male; Mice, Inbred C57BL; Mice, Transgenic; Parkinsonian Disorders; Receptors, Neurotransmitter; Serotonin; Transcription Factors | 2015 |
Differential effects of adenosine antagonists in two models of parkinsonian tremor.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Caffeine; Cholinergic Agonists; Disease Models, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Synergism; Jaw; Male; Parkinsonian Disorders; Pimozide; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Tacrine; Theophylline; Tremor; Triazoles | 2009 |
Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Corpus Striatum; Dopamine; Drug Administration Routes; Drug Synergism; Electron Transport Complex II; gamma-Aminobutyric Acid; Huntington Disease; Male; Malonates; Mice; Mitochondria; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Theobromine; Tyrosine 3-Monooxygenase; Xanthines | 2003 |
Adenosine A2A receptors and depression.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Caffeine; Depression; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Haloperidol; Mice; Mice, Knockout; Motor Activity; Neurotransmitter Agents; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Triazines; Triazoles | 2003 |
Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Binding, Competitive; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Humans; Ligands; Mefloquine; Mice; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Phenethylamines; Purines; Pyrimidines; Radioligand Assay; Rats; Triazines; Triazoles | 2003 |
Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adenosine; Adrenergic Agents; Animals; Caffeine; Corpus Striatum; Dynorphins; Dyskinesias; Enkephalins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; RNA, Messenger | 2006 |
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Exploratory Behavior; Levodopa; Male; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Sympatholytics; Triazoles | 2007 |
The metabolic rate and vulnerability of dopaminergic neurons, and adenosine dynamics in the cerebral cortex, nucleus accumbens, caudate nucleus, and putamen of the common marmoset.
Topics: Adenosine; Animals; Callithrix; Caudate Nucleus; Cerebral Cortex; Disease Models, Animal; Dopamine; Microdialysis; Neural Conduction; Nucleus Accumbens; Parkinsonian Disorders; Putamen | 2000 |